The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) shows every sign of being modestly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $80.95 per share and the market cap of $186 billion, Novo Nordisk A/S stock is believed to be modestly overvalued. GF Value for Novo Nordisk A/S is shown in the chart below.
Because Novo Nordisk A/S is relatively overvalued, the long-term return of its stock is likely to be lower than its business growth, which averaged 6.4% over the past three years and is estimated to grow 6.31% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Novo Nordisk A/S has a cash-to-debt ratio of 0.79, which ranks worse than 86% of the companies in Biotechnology industry. Based on this, GuruFocus ranks Novo Nordisk A/S's financial strength as 6 out of 10, suggesting fair balance sheet. This is the debt and cash of Novo Nordisk A/S over the past years:
It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. Novo Nordisk A/S has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $20.1 billion and earnings of $2.912 a share. Its operating margin is 41.62%, which ranks better than 95% of the companies in Biotechnology industry. Overall, the profitability of Novo Nordisk A/S is ranked 8 out of 10, which indicates strong profitability. This is the revenue and net income of Novo Nordisk A/S over the past years:
One of the most important factors in the valuation of a company is growth. Long-term stock performance is closely correlated with growth according to GuruFocus research. Companies that grow faster create more value for shareholders, especially if that growth is profitable. The average annual revenue growth of Novo Nordisk A/S is 6.4%, which ranks in the middle range of the companies in Biotechnology industry. The 3-year average EBITDA growth is 6.5%, which ranks in the middle range of the companies in Biotechnology industry.
One can also evaluate a company's profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely creating value for its shareholders. During the past 12 months, Novo Nordisk A/S's ROIC is 32.56 while its WACC came in at 4.65. The historical ROIC vs WACC comparison of Novo Nordisk A/S is shown below:
In conclusion, The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) is believed to be modestly overvalued. The company's financial condition is fair and its profitability is strong. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Novo Nordisk A/S stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
